$0.6
Live
Revenue is down for the last 2 quarters, 1.26M → 253.0K (in $), with an average decrease of 80.0% per quarter
Netprofit is down for the last 3 quarters, 54.50M → -4.37M (in $), with an average decrease of 136.1% per quarter
In the last 1 year, Haleon Plc Spon Ads has given 37.4% return, outperforming this stock by 123.4%
6.67%
Downside
Day's Volatility :16.42%
Upside
10.45%
8.33%
Downside
52 Weeks Volatility :88.68%
Upside
87.65%
Period | Acelrx Pharmaceuticals, Inc. | Russel 2000 | Index (Russel 2000) |
---|---|---|---|
3 Months | -39.03% | 0.0% | 0.0% |
6 Months | -11.52% | 2.0% | 2.0% |
1 Year | -83.82% | 5.3% | 5.3% |
3 Years | -97.75% | 19.9% | 19.9% |
Market Capitalization | 12.3M |
Book Value | $0.95 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -3.0 |
PEG Ratio | 0.0 |
Wall Street Target Price | 8.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -7770.36% |
Return On Assets TTM | -33.27% |
Return On Equity TTM | -68.59% |
Revenue TTM | 253.0K |
Revenue Per Share TTM | 0.03 |
Quarterly Revenue Growth YOY | -55.60000000000001% |
Gross Profit TTM | -3.3M |
EBITDA | -18.0M |
Diluted Eps TTM | -3.0 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -1.43 |
EPS Estimate Next Year | -0.69 |
EPS Estimate Current Quarter | -0.53 |
EPS Estimate Next Quarter | -0.5 |
What analysts predicted
Upside of 1233.33%
FY17 | Y/Y Change | |
---|---|---|
Revenue | 8.0M | ↓ 53.94% |
Net Income | -51.5M | ↑ 19.35% |
Net Profit Margin | -644.25% | ↓ 395.61% |
FY18 | Y/Y Change | |
---|---|---|
Revenue | 2.2M | ↓ 73.1% |
Net Income | -47.1M | ↓ 8.46% |
Net Profit Margin | -2.2K% | ↓ 1547.71% |
FY19 | Y/Y Change | |
---|---|---|
Revenue | 2.3M | ↑ 6.42% |
Net Income | -53.2M | ↑ 12.92% |
Net Profit Margin | -2.3K% | ↓ 133.95% |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 5.4M | ↑ 136.61% |
Net Income | -40.4M | ↓ 24.16% |
Net Profit Margin | -745.55% | ↑ 1580.36% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 2.8M | ↓ 47.97% |
Net Income | -35.1M | ↓ 13.08% |
Net Profit Margin | -1.2K% | ↓ 499.98% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 1.8M | ↓ 37.15% |
Net Income | 47.8M | ↓ 236.06% |
Net Profit Margin | 2.7K% | ↑ 3942.03% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 442.0K | ↑ 22000.0% |
Net Income | -8.7M | ↑ 9.56% |
Net Profit Margin | -2.0K% | ↑ 393887.56% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 570.0K | ↑ 28.96% |
Net Income | 70.7M | ↓ 914.65% |
Net Profit Margin | 12.4K% | ↑ 14359.46% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 507.0K | ↓ 11.05% |
Net Income | -6.8M | ↓ 109.55% |
Net Profit Margin | -1.3K% | ↓ 13728.38% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 1.3M | ↑ 149.31% |
Net Income | 54.5M | ↓ 907.48% |
Net Profit Margin | 4.3K% | ↑ 5643.46% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Revenue | 253.0K | - |
Net Income | -4.4M | ↓ 181.9% |
Net Profit Margin | -1.7K% | - |
FY17 | Y/Y Change | |
---|---|---|
Total Assets | 75.6M | ↓ 24.44% |
Total Liabilities | 112.1M | ↑ 6.39% |
FY18 | Y/Y Change | |
---|---|---|
Total Assets | 120.5M | ↑ 59.54% |
Total Liabilities | 116.3M | ↑ 3.76% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 91.4M | ↓ 24.21% |
Total Liabilities | 132.8M | ↑ 14.18% |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 66.3M | ↓ 27.43% |
Total Liabilities | 122.0M | ↓ 8.08% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 77.9M | ↑ 17.49% |
Total Liabilities | 113.8M | ↓ 6.77% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 47.5M | ↓ 39.04% |
Total Liabilities | 25.7M | ↓ 77.44% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 72.0M | ↓ 7.6% |
Total Liabilities | 110.2M | ↓ 3.11% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 56.1M | ↓ 22.01% |
Total Liabilities | 23.0M | ↓ 79.15% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 48.3M | ↓ 13.94% |
Total Liabilities | 20.8M | ↓ 9.66% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 47.5M | ↓ 1.7% |
Total Liabilities | 25.7M | ↑ 23.61% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 3.5M | ↓ 92.68% |
Total Liabilities | 3.3M | ↓ 87.23% |
Q2 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 17.7M | ↑ 409.93% |
Total Liabilities | 7.3M | ↑ 122.88% |
FY17 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -29.8M | ↑ 1.26% |
Investing Cash Flow | -10.0M | ↓ 651.13% |
Financing Cash Flow | 12.3M | ↓ 47511.54% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -29.1M | ↓ 2.32% |
Investing Cash Flow | -10.9M | ↑ 9.1% |
Financing Cash Flow | 75.0M | ↑ 508.62% |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -51.2M | ↑ 76.03% |
Investing Cash Flow | -36.6M | ↑ 236.15% |
Financing Cash Flow | 14.5M | ↓ 80.74% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -38.5M | ↓ 24.77% |
Investing Cash Flow | 34.1M | ↓ 193.37% |
Financing Cash Flow | 17.0M | ↑ 17.33% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -30.0M | ↓ 22.08% |
Investing Cash Flow | -26.1M | ↓ 176.52% |
Financing Cash Flow | 41.5M | ↑ 144.83% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -8.9M | ↑ 11.62% |
Investing Cash Flow | 20.2M | ↓ 554.52% |
Financing Cash Flow | -2.1M | ↓ 117.6% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -8.7M | ↓ 2.1% |
Investing Cash Flow | 9.2M | ↓ 54.54% |
Financing Cash Flow | -2.1M | ↑ 0.0% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -5.2M | ↓ 40.11% |
Investing Cash Flow | 4.4M | ↓ 51.57% |
Financing Cash Flow | -1.6M | ↓ 21.41% |
Sell
Neutral
Buy
Acelrx Pharmaceuticals, Inc. is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Acelrx Pharmaceuticals, Inc. | -38.47% | -11.52% | -83.82% | -97.75% | -99.19% |
![]() Neurocrine Biosciences Inc. | 5.78% | 17.2% | 13.1% | 16.42% | -7.26% |
![]() Haleon Plc Spon Ads | -1.33% | -0.85% | 34.27% | 9.99% | 9.99% |
![]() Zoetis Inc. | -3.36% | 6.62% | 18.9% | 9.85% | 95.75% |
![]() Viatris Inc. | -12.12% | 1.8% | 13.01% | -41.0% | -41.0% |
![]() Catalent, Inc. | 1.0% | -32.84% | -39.33% | -44.69% | 4.52% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Acelrx Pharmaceuticals, Inc. | 0.14 | NA | 0.0 | -1.43 | -0.69 | -0.33 | 0.0 | 0.95 |
![]() Neurocrine Biosciences Inc. | 63.9 | 63.9 | 1.87 | 2.35 | 0.11 | 0.08 | 0.0 | 18.99 |
![]() Haleon Plc Spon Ads | 23.82 | 23.82 | NA | 0.0 | 0.06 | 0.04 | 0.01 | 3.56 |
![]() Zoetis Inc. | 37.19 | 37.19 | 3.53 | 5.45 | 0.48 | 0.14 | 0.01 | 10.04 |
![]() Viatris Inc. | 7.07 | 7.07 | NA | 2.97 | 0.09 | 0.03 | 0.04 | 17.38 |
![]() Catalent, Inc. | 211.02 | NA | 1.18 | 1.01 | -0.05 | 0.0 | 0.0 | 25.61 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Acelrx Pharmaceuticals, Inc. | Buy | $12.3M | -99.19% | 0.14 | 0.0% |
![]() Neurocrine Biosciences Inc. | Buy | $11.0B | -7.26% | 63.9 | 10.54% |
![]() Haleon Plc Spon Ads | Buy | $37.9B | 9.99% | 23.82 | 10.78% |
![]() Zoetis Inc. | Buy | $81.3B | 95.75% | 37.19 | 26.92% |
![]() Viatris Inc. | Hold | $13.0B | -41.0% | 7.07 | 11.88% |
![]() Catalent, Inc. | Buy | $8.4B | 4.52% | 211.02 | -5.43% |
Rock Springs Capital Management LP
TANG CAPITAL MANAGEMENT LLC
Vanguard Group Inc
Values First Advisors Inc
BlackRock Inc
Geode Capital Management, LLC
acelrx pharmaceuticals inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of moderate-to-severe acute pain. the company’s product candidates, dsuvia™ (known as arx-04 outside of the united states) and zalviso®, are designed to deliver sufentanil, a strong opioid analgesic, via a non-invasive, sublingual formulation in medical supervised settings. dsuvia is designed to deliver sublingual tablets containing 30 mcg sufentanil via a disposable, pre-filled, single-dose applicator. the phase 3 clinical program has completed and assessed the investigational product in the treatment of moderate-to-severe acute pain in patients who had undergone surgery or who presented to an emergency room with trauma or injury. in clinical studies, dsuvia demonstrated reductions in pain intensity as early as 15-to-30 minutes after the start of dosing and the most common adverse events included nausea, headache, dizziness, and v
Organization | Acelrx Pharmaceuticals, Inc. |
Employees | 19 |
CEO | Mr. Vincent J. Angotti |
Industry | Health Technology |
Farmers National Banc Corp
$0.60
-10.54%
Revance Therapeutics Inc
$0.60
-10.54%
X-links Slvr Shrs Covrd Call
$0.60
-10.54%
Bny Mellon Ultra Short Income Etf
$0.60
-10.54%
Xeris Biopharma Holdings Inc
$0.60
-10.54%
Columbia Financial Inc
$0.60
-10.54%
Rumbleon Inc
$0.60
-10.54%
Innovator Growth-100 Power Buffer Etf - April
$0.60
-10.54%
Stealthgas Inc
$0.60
-10.54%